eli lilly retatrutide trial results orforglipron oral GLP-1 phase 3 weight loss Eli Lilly Obesity Drug Market

Efficacy of ertugliflozin on heart failure-related events in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease: results of the VERTIS CV trial

It also warned that patients should be asked about whether they are taking GLP-1 or dual GIP/GLP-1 RAs, as there is a possibility that patients may have purchased GLP-1 or dual GIP/GLP-1 RAs for aesthetic weight loss and may not readily disclose this information unless directly asked

Some studies also point to direct benefits for cardiac contractility and protection against oxidative stress in the heart

[DOI] [PubMed] [Google Scholar] 211.Ehrmann D, Kulzer B, Roos T, Haak T, Al-Khatib M, Hermanns N

For patients with cardiovascular risk factors, semaglutide is a risk reduction medication, not just a weight management tool

Log your doses, track your level, and bring a complete export to your next prescriber visit